
|Videos|November 9, 2022
Dr. Albala on financial implications of emergence of PSMA-PET imaging
Author(s)Urology Times staff
“What’s important is that we get these studies approved so that our patients aren’t suffering any further economic burdens by having this new type of imaging being put forward,” says David Albala, MD.
Advertisement
In this video, urologist David Albala, MD, explains financial issues related to the emergence of PSMA-PET imaging as a critical component of the prostate cancer management paradigm. Albala is discussing PSMA-PET imaging during the CME program at the
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Sarah Azari, MD, on early sexual health education for women with bladder cancer
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5






